Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer

Inclusion Criteria:

* Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)
* Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)
* Measurable disease by RECIST 1.1 criteria (Part 2 only)
* Willing and able to consent for self to participate in study
* Progressive or recurrent disease after prior systemic chemotherapy regimen
* Age ≥ 18 years
* ECOG performance status of 0 or 1
* Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade ≤ 1 or baseline (except alopecia)
* Adequate organ function

Exclusion Criteria:

* Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.
* Prior treatment with TRC105
* History of hypersensitivity reaction to antimetabolite therapy
* Receipt of an investigational agent within 28 days of starting study treatment
* Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment
* Minor surgical procedures within 14 days prior to first dose of TRC105
* History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease
* Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months
* Uncontrolled chronic hypertension defined as systolic \> 140 or diastolic \> 90 despite optimal therapy
* Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia
* Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105
* Cardiac dysrhythmias of NCI CTCAE Grade ≥ 2 within the last month
* Hemorrhage within 28 days of starting study treatment
* Unhealed wounds within 28 days of starting study treatment
* History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment
* Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness
* Known active viral or nonviral hepatitis
* History of hypersensitivity reaction to human or mouse antibody products
* Lung cancer with central chest lesions
* Pregnancy or breastfeeding